Liver Transplantation News and Research

RSS
Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

Increasing number of sickest liver transplant candidates delisted from wait list, study finds

Increasing number of sickest liver transplant candidates delisted from wait list, study finds

Researchers find prevalence of steatosis in liver transplant recipients

Researchers find prevalence of steatosis in liver transplant recipients

Analysis reveals improved survivorship for acute liver failure patients

Analysis reveals improved survivorship for acute liver failure patients

Renal risk factors for NA-treated HBV patients identified

Renal risk factors for NA-treated HBV patients identified

Modified protein appears to reverse liver fibrosis, cirrhosis in rats

Modified protein appears to reverse liver fibrosis, cirrhosis in rats

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

Study finds that living liver donors highly satisfied with donation process

Study finds that living liver donors highly satisfied with donation process

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

SLU hepatologist receives $150,000 grant to study preventative strategies for TPN-associated disorders

SLU hepatologist receives $150,000 grant to study preventative strategies for TPN-associated disorders

Hiroshima University researchers report promising new avenue for treating hepatitis B

Hiroshima University researchers report promising new avenue for treating hepatitis B

Surgeons participate in record-setting day of organ transplantation at Baylor University Medical Center

Surgeons participate in record-setting day of organ transplantation at Baylor University Medical Center

New DNA analysis may guide personalized management of hepatocellular carcinoma

New DNA analysis may guide personalized management of hepatocellular carcinoma

New study of DCD liver transplantations finds no significant link between donor age and organ survival

New study of DCD liver transplantations finds no significant link between donor age and organ survival

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.